ELDN - NASDAQ
Eledon Pharmaceuticals, Inc.
$3.49
+1.5%Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
At a Glance
Live SnapshotEledon Pharmaceuticals, Inc. Management Team
Dr. David-Alexandre C. Gros M.D., Ph.D.
Chief Executive Officer & Non Independent Director
Compensation
$1,067,936
Mr. Paul Sean Little
Chief Financial Officer
Compensation
$724,489
Dr. Eliezer Katz F.A.C.S., FACS, M.D.
Chief Medical Officer
Dr. David Hovland Ph.D.
Chief Regulatory Officer
Mr. Bryan E. Smith J.D.
General Counsel, Corporate Secretary & Chief Compliance Officer
Compensation
$377,136
Dr. Steven N. Perrin Ph.D.
President, Chief Scientific Officer & Non Independent Director
Compensation
$784,127
Ms. Marina Escudero
Vice President & Head of Clinical Operations
Mr. John Herberger
Vice President of Technical Operations
Eledon Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $125K worth of ELDN shares, with no selling activity reported.
3 Months
30.9K
124.71K
0
0.00
+125K
+$125K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Robinson James A. Jr.
Director
$125K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $125K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
ELDN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 30, 2024 | July 10, 2024 | 2024 | |
DEF 14A DEF 14A N/A | May 01, 2023 | May 01, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 21, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | November 20, 2020 | December 18, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | March 31, 2020 | May 12, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 15, 2019 | July 11, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 13, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.